1. Home
  2. LNZA vs ESPR Comparison

LNZA vs ESPR Comparison

Compare LNZA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LanzaTech Global Inc.

LNZA

LanzaTech Global Inc.

HOLD

Current Price

$14.94

Market Cap

92.3M

Sector

Industrials

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.61

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNZA
ESPR
Founded
2005
2008
Country
United States
United States
Employees
384
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.3M
731.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
LNZA
ESPR
Price
$14.94
$2.61
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$14.00
$7.60
AVG Volume (30 Days)
56.5K
5.2M
Earning Date
05-18-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
$2.92
Revenue Next Year
$113.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$0.14
$0.73
52 Week High
$34.49
$4.18

Technical Indicators

Market Signals
Indicator
LNZA
ESPR
Relative Strength Index (RSI) 48.66 41.71
Support Level $10.01 $2.37
Resistance Level $29.51 $3.02
Average True Range (ATR) 4.38 0.19
MACD -0.41 0.03
Stochastic Oscillator 21.95 42.02

Price Performance

Historical Comparison
LNZA
ESPR

About LNZA LanzaTech Global Inc.

LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: